Development of Enabling Technologies for Clinical Ultrahigh Field Body MRI

临床超高场体 MRI 使能技术的开发

基本信息

批准号：
10533352
负责人：
Gregory John Metzger
金额：
$ 60.45万
依托单位：
UNIVERSITY OF MINNESOTA
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-04-15 至 2024-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10533352
关键词：
Accounting Address Adopted Adoption Anatomy Architecture Beds Biomedical Research Biopsy Cancer Detection Clinical Compensation Databases Deposition Detection Development Diagnosis Diagnostic Electromagnetic Fields Electromagnetics Electronics Environment FDA approved Goals Head Heating Human Human body Image Imaging Device Individual Joints Knee Lesion Libraries Location Magnetic Resonance Imaging Malignant neoplasm of prostate Methods Modality Modeling Motion Noise Outcome Pathology Patient Care Patient imaging Patient-Focused Outcomes Patients Performance Physiologic pulse Physiological Population Database Prostate Prostatectomy Protocols documentation Reader Reproducibility Research Resolution Safety Scanning Signal Transduction System Techniques Technology Testing Time anatomic imaging arterial spin labeling cancer imaging clinical imaging clinical translation design expectation improved improved outcome innovation invention patient population radio frequency targeted imaging tool transmission process virtual

项目摘要

The advent of clinically approved imaging at 7 Tesla (7T) has been met with high expectations. The potential benefits of increased signal-to-noise ratio (SNR), new contrasts and unprecedented resolution promise to extend what once was a tool for biomedical research into an imaging device defining state of the art patient care. The benefit of obtaining FDA approval is that it creates the opportunity for clinicians to investigate its true potential and to discover the applications where it uniquely impacts patient care. The current FDA approval however is only for head and knee applications, and even then, the MRI scanner is limited to using only a fraction of its installed functionality. Parallel transmit (pTx), a functionality that can tackle some of the biggest challenges facing ultrahigh field (UHF) MRI, has not been sufficiently developed, integrated and validated to safely use in the clinical setting. These challenges such as non-uniform transmit fields and issues with local heating scale with the size of the object being imaged. While imaging the head and knee can manage without this functionality, pTx it is an absolute necessity for applications in the human torso. While 7T has shown great potential at imaging targets in the torso in the research setting, there is the critical question of how to expand upon these promising results. We believe that several enabling technologies need to be further developed and integrated prior to obtaining FDA approval. These developments are addressed in three technical aims. The first is the development and optimization of radiofrequency (RF) coils to efficiently transmit RF energy into and receive signals from the body in order to realize the promised gains in SNR compared to lower field strengths. The second is the construction of a virtual database of human body models and strategies for overcoming the current limitations of assuming overly restrictive safety factors when attempting to use the pTx system. The third involves integrating pTx functionality into an extended multi-parametric prostate imaging protocol and motion compensation strategies through sequence tailored pTx solutions and optimization. A final translational aim will use the prostate as a testbed to explore the RF coils and pTx enabled sequences in a patient study comparing cancer detection and imaging metrics with the same patients imaged at 3T. Upon successful completion of these developmental and translational aims, we will have overcome the barriers to enabling clinical torso imaging at UHF and verified its effective use in a clinical setting. The outcomes of this project will be critical component in expanding the FDA approved indications for 7T. Once in the hands of clinicians, establishing the unique impact of UHF imaging on patient outcomes will greatly benefit from being able to use 7T as a front-line scanning modality.

临床批准的 7 特斯拉 (7T) 成像技术的出现满足了人们的很高期望。潜力提高信噪比 (SNR)、新对比度和前所未有的分辨率的优势有望扩展它曾经是一种用于生物医学研究的成像设备工具，定义了最先进的患者护理水平。这获得 FDA 批准的好处是它为临床医生创造了研究其真正潜力的机会并发现它对患者护理产生独特影响的应用。然而，目前 FDA 的批准是仅适用于头部和膝盖应用，即使如此，MRI 扫描仪也仅限于仅使用其一小部分安装的功能。并行传输 (pTx)，一种可以解决所面临的一些最大挑战的功能超高场 (UHF) MRI 尚未得到充分开发、集成和验证，无法安全地用于临床环境。这些挑战例如不均匀的传输场以及局部加热规模的问题被成像物体的大小。虽然无需此功能即可对头部和膝盖进行成像，但 pTx 对于人体躯干的应用来说，这是绝对必要的。虽然7T在成像方面表现出了巨大的潜力在研究环境中的躯干目标中，存在一个关键问题：如何扩展这些有前途的目标结果。我们认为，在实现这一目标之前，需要进一步开发和集成一些使能技术获得 FDA 批准。这些发展体现在三个技术目标中。首先是发展射频 (RF) 线圈的优化，以有效地将 RF 能量传输到设备中并从设备接收信号与较低场强相比，以实现信噪比的承诺增益。第二个是构建人体模型虚拟数据库和克服当前局限性的策略尝试使用 pTx 系统时假设过度限制的安全因素。第三个涉及整合 pTx 功能融入扩展的多参数前列腺成像协议和运动补偿通过序列定制的 pTx 解决方案和优化来制定策略。最终的转化目标将使用前列腺作为在比较癌症检测的患者研究中探索 RF 线圈和 pTx 启用序列的测试平台以及相同患者在 3T 下成像的成像指标。成功完成这些发展后和转化目标，我们将克服障碍，实现超高频临床躯干成像并得到验证其在临床环境中的有效使用。该项目的成果将成为扩大 FDA 规模的关键组成部分 7T 的批准适应症。一旦到达临床医生手中，就可以确定 UHF 成像对患者的独特影响如果能够使用 7T 作为一线扫描方式，患者的治疗效果将大大受益。